Beyond the Golden Hour: Treating Acute Stroke in the Platinum 30 Minutes.
blood pressure
cerebral hemorrhage
reperfusion
thrombectomy
transient ischemic attack
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
13
5
2022
medline:
28
7
2022
entrez:
12
5
2022
Statut:
ppublish
Résumé
To emphasize treatment speed for time-sensitive conditions, emergency medicine has developed not only the concept of the golden hour, but also the platinum half-hour. Patients with acute stroke treated within the first half-hour of onset have not been previously characterized. In this cohort study, we analyzed patients enrolled in the FAST-MAG (Field Administration of Stroke Therapy-Magnesium) trial, testing paramedic prehospital start of neuroprotective agent ≤2 hours of onset. The features of all acute cerebral ischemia, and intracranial hemorrhage patients with treatment starting at ≤30 m of last known well were compared with later-treated patients. Among 1680 patients, 203 (12.1%) received study agents within 30 minutes of last known well. Among platinum half-hour patients, median onset-to-treatment time was 28 minutes (interquartile range, 25-30), and final diagnoses were acute cerebral ischemia in 71.8% (ischemic stroke, 61.5%, TIA 10.3%); intracranial hemorrhage in 26.1%; and mimic in 2.5%. Clinical features among platinum half-hour patients were largely similar to later-treated patients and included age 69 (interquartile range, 57-79), 44.8% women, prehospital Los Angeles Motor Scale median 4 (3-5), and early-postarrival National Institutes of Health Stroke Scale deficit 8 (interquartile range, 3-18). Platinum half-hour acute cerebral ischemia patients did have more severe prehospital motor deficits and younger age; platinum half-hour intracranial hemorrhage patients had more severe motor deficits, were more often female, and less often of Hispanic ethnicity. Outcomes at 3 m in platinum half-hour patients were comparable to later-treated patients and included freedom-from-disability (modified Rankin Scale score, 0-1) in 35.5%, functional independence (modified Rankin Scale score, 0-2) in 53.2%, and mortality in 17.7%. Prehospital initiation permits treatment start within the platinum half-hour after last known well in a substantial proportion of acute ischemic and hemorrhagic stroke patients, accounting for more than 1 in 10 enrolled in a multicenter trial. Hyperacute platinum half-hour patients were largely similar to later-treated patients and are an attainable target for treatment in prehospital stroke trials.
Sections du résumé
BACKGROUND
To emphasize treatment speed for time-sensitive conditions, emergency medicine has developed not only the concept of the golden hour, but also the platinum half-hour. Patients with acute stroke treated within the first half-hour of onset have not been previously characterized.
METHODS
In this cohort study, we analyzed patients enrolled in the FAST-MAG (Field Administration of Stroke Therapy-Magnesium) trial, testing paramedic prehospital start of neuroprotective agent ≤2 hours of onset. The features of all acute cerebral ischemia, and intracranial hemorrhage patients with treatment starting at ≤30 m of last known well were compared with later-treated patients.
RESULTS
Among 1680 patients, 203 (12.1%) received study agents within 30 minutes of last known well. Among platinum half-hour patients, median onset-to-treatment time was 28 minutes (interquartile range, 25-30), and final diagnoses were acute cerebral ischemia in 71.8% (ischemic stroke, 61.5%, TIA 10.3%); intracranial hemorrhage in 26.1%; and mimic in 2.5%. Clinical features among platinum half-hour patients were largely similar to later-treated patients and included age 69 (interquartile range, 57-79), 44.8% women, prehospital Los Angeles Motor Scale median 4 (3-5), and early-postarrival National Institutes of Health Stroke Scale deficit 8 (interquartile range, 3-18). Platinum half-hour acute cerebral ischemia patients did have more severe prehospital motor deficits and younger age; platinum half-hour intracranial hemorrhage patients had more severe motor deficits, were more often female, and less often of Hispanic ethnicity. Outcomes at 3 m in platinum half-hour patients were comparable to later-treated patients and included freedom-from-disability (modified Rankin Scale score, 0-1) in 35.5%, functional independence (modified Rankin Scale score, 0-2) in 53.2%, and mortality in 17.7%.
CONCLUSIONS
Prehospital initiation permits treatment start within the platinum half-hour after last known well in a substantial proportion of acute ischemic and hemorrhagic stroke patients, accounting for more than 1 in 10 enrolled in a multicenter trial. Hyperacute platinum half-hour patients were largely similar to later-treated patients and are an attainable target for treatment in prehospital stroke trials.
Identifiants
pubmed: 35545939
doi: 10.1161/STROKEAHA.121.036993
pmc: PMC9329219
mid: NIHMS1801877
doi:
Substances chimiques
Platinum
49DFR088MY
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2426-2434Subventions
Organisme : NINDS NIH HHS
ID : U01 NS044364
Pays : United States
Références
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Stroke. 2020 Nov;51(11):3425-3432
pubmed: 33104466
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
Bioinformatics. 2018 Oct 1;34(19):3365-3376
pubmed: 29726967
JAMA. 2013 Jun 19;309(23):2480-8
pubmed: 23780461
Soins. 2014 Sep;(788):14-5
pubmed: 25464628
Stroke. 2006 Jan;37(1):263-6
pubmed: 16339467
N Engl J Med. 2015 Feb 5;372(6):528-36
pubmed: 25651247
Circulation. 2017 Jan 10;135(2):128-139
pubmed: 27815374
Stroke. 2007 Nov;38(11):3097-115
pubmed: 17901393
JAMA Neurol. 2015 Jan;72(1):25-30
pubmed: 25402214
Stroke. 2009 Mar;40(3):833-40
pubmed: 19150875
Lancet Neurol. 2019 Jan;18(1):46-55
pubmed: 30413385
Int J Stroke. 2014 Feb;9(2):220-5
pubmed: 24444117
Emerg Med J. 2013 Dec;30(12):1048-55
pubmed: 23258373
Lancet. 2014 Nov 29;384(9958):1929-35
pubmed: 25106063
Stroke. 2016 Jun;47(6):1651-3
pubmed: 27143274
Stroke. 2020 Aug;51(8):2553-2557
pubmed: 32611286
Int J Stroke. 2014 Feb;9(2):215-9
pubmed: 24444116
JAMA. 2019 Jul 16;322(3):252-263
pubmed: 31310296
West J Emerg Med. 2014 Mar;15(2):251-9
pubmed: 24926394